GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » Piotroski F-Score

Equillium (Equillium) Piotroski F-Score : 3 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Equillium has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Equillium's Piotroski F-Score or its related term are showing as below:

EQ' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 3

During the past 7 years, the highest Piotroski F-Score of Equillium was 4. The lowest was 2. And the median was 3.


Equillium Piotroski F-Score Historical Data

The historical data trend for Equillium's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Piotroski F-Score Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 2.00 2.00 3.00 4.00 3.00

Equillium Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 6.00 6.00 3.00

Competitive Comparison of Equillium's Piotroski F-Score

For the Biotechnology subindustry, Equillium's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Equillium's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -3.94 + -3.343 + -3.71 + -2.342 = $-13.34 Mil.
Cash Flow from Operations was -7.995 + -6.215 + -1.909 + -5.664 = $-21.78 Mil.
Revenue was 8.879 + 9.124 + 8.87 + 9.211 = $36.08 Mil.
Gross Profit was 8.879 + 9.124 + 8.87 + 9.211 = $36.08 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(78.421 + 71.79 + 58.764 + 55.225 + 50.53) / 5 = $62.946 Mil.
Total Assets at the begining of this year (Dec22) was $78.42 Mil.
Long-Term Debt & Capital Lease Obligation was $0.38 Mil.
Total Current Assets was $49.35 Mil.
Total Current Liabilities was $27.57 Mil.
Net Income was -37.417 + -14.129 + -13.655 + 2.773 = $-62.43 Mil.

Revenue was 0 + 0 + 0 + 15.759 = $15.76 Mil.
Gross Profit was 0 + 0 + 0 + 15.759 = $15.76 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(85.405 + 74.235 + 62.472 + 48.631 + 78.421) / 5 = $69.8328 Mil.
Total Assets at the begining of last year (Dec21) was $85.41 Mil.
Long-Term Debt & Capital Lease Obligation was $4.06 Mil.
Total Current Assets was $76.74 Mil.
Total Current Liabilities was $32.04 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Equillium's current Net Income (TTM) was -13.34. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Equillium's current Cash Flow from Operations (TTM) was -21.78. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-13.335/78.421
=-0.17004374

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-62.428/85.405
=-0.73096423

Equillium's return on assets of this year was -0.17004374. Equillium's return on assets of last year was -0.73096423. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Equillium's current Net Income (TTM) was -13.34. Equillium's current Cash Flow from Operations (TTM) was -21.78. ==> -21.78 <= -13.34 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.384/62.946
=0.00610047

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=4.063/69.8328
=0.05818183

Equillium's gearing of this year was 0.00610047. Equillium's gearing of last year was 0.05818183. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=49.349/27.573
=1.7897581

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=76.735/32.038
=2.39512454

Equillium's current ratio of this year was 1.7897581. Equillium's current ratio of last year was 2.39512454. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Equillium's number of shares in issue this year was 35.158. Equillium's number of shares in issue last year was 34.374. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=36.084/36.084
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15.759/15.759
=1

Equillium's gross margin of this year was 1. Equillium's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=36.084/78.421
=0.46013185

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=15.759/85.405
=0.18452081

Equillium's asset turnover of this year was 0.46013185. Equillium's asset turnover of last year was 0.18452081. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Equillium has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Equillium  (NAS:EQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Equillium Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Equillium's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium (Equillium) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Executives
Jason A Keyes officer: Chief Financial Officer 3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Barbara Troupin director C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Christine Zedelmayer officer: Sr. Vice President and COO 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly director, officer: Chief Scientific Officer 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc 10 percent owner P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui 10 percent owner NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu director P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman officer: Chief Development Officer 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott director 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon 10 percent owner CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel director, officer: President, CBO C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555

Equillium (Equillium) Headlines